Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus naltrexone for suicidal or treatment-resistant major depressive disorder
ChiCTR2100051258Phase 4Recruiting
- Sponsor
- The Affiliated Brain Hospital of Guangzhou Medical University
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in major depressive disorder (MDD), major depressive episode (MDE) and treatment-resistant depression (TRD) comparing naltrexone + esketamine with placebo + esketamine (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale. Started Sep 2021; status: recruiting.
02
Drugs
esketaminenaltrexone
03
Conditions
major depressive disorder (MDD)major depressive episode (MDE)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ChiCTR2100051258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051258.